Trevogrumab Preserves 70% of Muscle Lost During GLP-1 Weight Loss in Phase 2
REGN sits 36% above its 52-week low of $541.
Summary
Regeneron's Phase 2 COURAGE trial met its primary endpoint, showing trevogrumab preserved lean mass at 26 and 52 weeks when added to semaglutide. MRI substudy data showed up to 70% preservation of thigh muscle volume. A pre-specified subgroup analysis found greater benefit in patients with low lean mass at baseline. The company plans a Phase 2 trial in older adults with obesity and decreased muscle mass. This addresses a key concern with GLP-1 therapies and supports a differentiated obesity pipeline.
At the time of this announcement, REGN was trading at $734.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.6B. The 52-week trading range was $541.00 to $859.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.